Study Reveals How a Common Parkinson's Drug May Reduce Levodopa Efficacy via Gut Microbiome

How Levodopa Works in Parkinson’s Disease

Levodopa is the gold-standard treatment for Parkinson’s disease, a condition characterized by reduced dopamine production in the brain. As an oral medication, levodopa is absorbed and crosses the blood-brain barrier, where it is converted into dopamine to alleviate symptoms.

“This drug is a way for the body to externally receive dopamine,” says Andrew Verdegaal, lead author of the study and a postdoctoral associate in the lab of senior author Andrew Goodman, PhD. “But it has to get into the brain to have an effect.”

COMT Inhibitors: Their Role and Unintended Consequences

As Parkinson’s disease progresses, patients often require additional medications to manage symptoms. One such class of drugs is catechol-O-methyltransferase inhibitors (COMT-Is), which are prescribed to increase the amount of levodopa that reaches the brain.

COMT-Is work by blocking enzymes that chemically modify levodopa before it crosses the blood-brain barrier, thereby enhancing its efficacy. However, the new study from Yale School of Medicine (YSM) reveals a counterproductive effect: COMT-Is can alter the gut microbiome in ways that reduce levodopa’s effectiveness.

Gut Microbiome Changes May Hinder Levodopa Absorption

The research, published in Nature Microbiology, found that COMT-Is possess antibacterial properties that disrupt the balance of gut bacteria. When susceptible bacteria are killed off, others—including Enterococcus faecalis—thrive. This bacterium contains an enzyme that metabolizes levodopa, preventing it from reaching the brain.

“We found a counterproductive effect of this drug that’s meant to increase levodopa efficacy,” Verdegaal explains. “While we generally think of the liver as the mediator for drug-drug interactions, this interaction occurs instead through the gut microbiome.”

Key Findings and Implications

• COMT-Is can alter gut microbiome composition, promoting the growth of bacteria like Enterococcus faecalis that break down levodopa.
• Patients with higher levels of E. faecalis in their gut may experience reduced benefits from levodopa.
• The study suggests that co-prescribed drugs may interact with the microbiome in ways that affect treatment efficacy.

“People often require co-prescription of multiple drugs,” Verdegaal notes. “While Parkinson’s disease is one example, this study suggests that we should look more closely at the role of the microbiome in response to other co-prescribed drugs.”

Broader Impact on Drug Efficacy and Personalized Medicine

The findings add to growing evidence that individual differences in gut microbiomes may explain why patients respond differently to the same medication. Verdegaal hopes the research serves as a foundation for further exploration of microbiome-drug interactions.

“I hope our research is a stepping stone to understand this in a wider context,” he says.

Study Funding and Source

The research was supported by the National Institutes of Health and Yale University. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Source: Yale School of Medicine